Stock VRDN VIRIDIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Market Closed - Nasdaq
Other stock markets
 01:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
12.76 USD -3.41% Intraday chart for Viridian Therapeutics, Inc. +4.76% -41.41%
11/06 Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
11/06 Sector Update: Health Care MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Sector Update: Health Care
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as US FOMC Meeting Begins
Viridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-To-Severe Thyroid Eye Disease
Viridian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer
Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer
Viridian Therapeutics Prices Common Stock Offering at $21 per Share
Viridian Therapeutics Starts Underwritten Stock Offering; Shares Fall After Hours
Viridian Therapeutics, Inc. Provides Key Updates on its Anti-Insulin-Like Growth Factor 1 Receptor (IGF-1R) Programs in Thyroid Eye Disease and its Programs Targeting FcRn
Viridian Therapeutics, Inc. Announces Executive Changes
Viridian Therapeutics Q3 Loss Widens, Revenue Drops
Viridian Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors
Viridian Therapeutics Names Stephen Mahoney Chief Executive
Viridian Therapeutics, Inc. Appoints Thomas Beetham as Chief Operating Officer
Viridian Therapeutics, Inc. Announces Management Changes
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. News Viridian Therapeutics, Inc.
  5. Other languages